NCT04372537

Brief Summary

Electroneuromyography (ENMG) is a regular neurological investigation that might be painful or unpleasant. Medical hypnosis can avoid these sensations, and is more and more performed during other medico-technical procedures (radiology, biopsies for example). This study aims at evaluate the effect of medical hypnosis on pain and anxiety during ENMG, in patients presenting with anxiety. Our hypothesis is that the anxiety and pain during ENMG will be lower in patients with hypnosis compared to patients with standard care. This will allow us to help patients with this tool during most ENMG procedures, and extend it to other electrophysiological procedures in the future.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable anxiety

Timeline
Completed

Started Mar 2021

Longer than P75 for not_applicable anxiety

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 29, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 4, 2020

Completed
11 months until next milestone

Study Start

First participant enrolled

March 22, 2021

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 29, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 29, 2024

Completed
Last Updated

December 23, 2025

Status Verified

December 1, 2025

Enrollment Period

3.1 years

First QC Date

April 29, 2020

Last Update Submit

December 17, 2025

Conditions

Keywords

hypnosiselectro-neuro-myographyanxietypainanalgesia

Outcome Measures

Primary Outcomes (1)

  • Pain score evaluated by analogue visual scale

    EVA measures the intensity of pain on a scale of 0 (no pain) to 10 (maximum pain imaginable)

    at the end of electro-neuro-myography exam

Secondary Outcomes (2)

  • Anxiety score evaluated by analogue visual scale

    at the end of electro-neuro-myography exam

  • anxiety score evolution evaluated by analogue visual scale

    between baseline and at the end of electro-neuro-myography exam

Study Arms (2)

Hypnosis

EXPERIMENTAL

Patients will benefit from formal hypnosis (trance induction, hypno analgesia, comfort suggestions) and/or conversational hypnosis (confusion, distraction, use of chosen words, goodwill using verbal and non verbal languages). They will also get to be informed of the proceedings of the performed examination as the standard procedure group.

Behavioral: hypnosis

Standard procedure group.

ACTIVE COMPARATOR

Patients will be informed of the proceedings of the performed examination, without using any hypnosis technique. This corresponds to the standard clinical procedures used while performing an electroneuromyogram.

Behavioral: standard care

Interventions

hypnosisBEHAVIORAL

use of hypnosis.

Hypnosis
standard careBEHAVIORAL

standard clinical procedure

Standard procedure group.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient admitted for ENMG manifesting: spontaneous verbal anxiety about taking the test/- a state of anxiety about the examination, as evidenced by a dark colour on a wellness scale used in the unit
  • with a good understanding of the French language
  • able to complete self-questionnaires
  • Patient who has given written consent to participate in the trial
  • Socially insured patient

You may not qualify if:

  • algesic sensitivity disorders
  • known history of psychiatric illness or current known psychiatric illness: severe depression, psychosis
  • Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign the consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hopital Roger Salengro, CHU Lille

Lille, 59037, France

Location

MeSH Terms

Conditions

Anxiety DisordersPainAgnosia

Interventions

HypnosisStandard of Care

Condition Hierarchy (Ancestors)

Mental DisordersNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

Mind-Body TherapiesComplementary TherapiesTherapeuticsPsychotherapyBehavioral Disciplines and ActivitiesQuality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Perrine Bocquillon, MD

    University Hospital, Lille

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 29, 2020

First Posted

May 4, 2020

Study Start

March 22, 2021

Primary Completion

April 29, 2024

Study Completion

April 29, 2024

Last Updated

December 23, 2025

Record last verified: 2025-12

Locations